REVIEWS

The Written Opinion of the European Patent Office, the International Search Authority of World Intellectual Property Organisation (WIPO) while examining our International Patent Application (PCT/IB2016/051060) WO/2016/142799 A FLUID INJECTING SYSTEM WITH NEEDLE RETRACTION BY VACUUM has opined:

“The technical effect of these features is that the injector is reusable while the only parts to be discarded are the needle hub and the medicament cartridge. As a result a cheaper and friendlier to the environment system is achieved without an increased risk of needle injuries.”  

In the final stage in First Mile Innovation Challenge – CAMTech organised by Massachusetts General Hospital in association with GE Sustainable Healthcare Solutions, the reviewers' opined:

“The proposed novel syringe has great potential to reduce medical waste and increase safety for medical professionals. It is responsive to the WHO call for reduction in reused syringes. This is clearly a breakthrough technology as evidenced by their patent applications and their early recognition.”  

On August 11th, 2017, the Engineering Export Promotion Council of India (EEPC India) has strongly endorsed our technology in following words:

"India's 'Futuristic Safe Injection System-2020' is ready for industrial commercialisaton. 

WHO’s Global Health Initiative for Needle Safety is urging countries to transition by 2020 to the exclusive use of the new “smart” syringes.

The ‘Make in India’ breakthrough can potentially make India become sole exporter of this smart indigenous technology to meet the domestic and international demands.”

On the occasion of World Hepatitis Day-2017, the Consortium for Affordable Medical Technologies (CAMTech) of Massachusetts General Hospital Global Health (MGH) has endorsed our technology as

"Futuristic Safe Injection System: self-retarctable safety syringes to reduce risk of needle stick #WorldHepatitisDay"

Dr. Anand Pandey, General Manager of Nectar Lifesciences Ltd, India has opined:

”The complete transfer of drug substances from vial / ampoules is never possible as some quantity of drug remain be inside of bottle, therefore FDA recommend to fill additional quantity about 5-15% of extra quantity to ensure the label potency / prescribed amount of drug has been comfortably transferred into syringes for injection. Therefore, to compensate the dispensing losses, it is always necessary to add addition 5-15% additional drug substance in final formulation dosage form i.e. vials, ampoules. This additional drug quantity is called ‘overfill amount’, is mandatory and Drug Companies do submit validation report for the their addition quantities to regulatory agencies. The ‘overfill quantity’ is mandatory disclosure and drug companies do submit data to regulatory agencies for final IND approval for any injection. Because of this, any vials or ampoules for injection always contains about 5-15% addition drug substances to confirm and ensure that recommended dose gets transferred into syringe for IV/IM injection. This additional extra drug quantity is absolutely a waste of drug product and cost of this extra mount huge. The minimum of 5% saving of drug substance is enormous and unimaginable saving to drug companies and it is a direct input cost saving. In comparison to this savings the packaging material saving and initial cost is simply peanut, A  Game Changer. Further, this overfill quantity  goes with packaging material waste and required extra care, if not compromised during plastic recycling….this further leads a more impure and contaminated recycled plastic……the hazards of this multi drug contaminated plastics is very unknown and as of now there is no study matrix available to visualize and estimate the danger situation. In light of above facts, the Futuristic Safe Injection System is a extraordinary achievement and gives solution to many critical problem along with a better economical choice.”